Breaking Traditions: Evaluating Single Fraction Radiation in Indolent Lymphoma

IF 3.3 4区医学 Q2 HEMATOLOGY

Hematological Oncology Pub Date : 2024-12-08 DOI:10.1002/hon.70015

Hazim S. Ababneh, Chirayu G. Patel

{"title":"Breaking Traditions: Evaluating Single Fraction Radiation in Indolent Lymphoma","authors":"Hazim S. Ababneh, Chirayu G. Patel","doi":"10.1002/hon.70015","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>As indolent non-Hodgkin's lymphomas (iNHLs) are very radiosensitive, radiation treatment (RT) has been established as an essential curative and palliative modality for early and advanced stages of the disease. Several studies have explored the role of very low-dose RT for palliation in indolent non-Hodgkin's lymphomas, demonstrating that this approach can lead to high rates of local control, and thereby, help improve the quality of life for these patients. While the most common schedule of very low-dose RT used in the palliative setting is 4Gy in 2 fractions, which was established in the landmark FoRT trial, this requires patients to be available for two RT sessions, increasing the financial and opportunity costs for the patient. Currently, data regarding the use of a single fraction of very low-dose RT (4Gy) for treating iNHLs in the palliative setting is still lacking. In this viewpoint, we aim to draw attention to this approach, where we emphasize the need for further exploration of the single-dose fractionation schedule as a non-toxic, simple, and easy treatment approach for iNHLs, which would inform future clinical trials to investigate this dose/fractionation.</p>\n </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.70015","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

As indolent non-Hodgkin's lymphomas (iNHLs) are very radiosensitive, radiation treatment (RT) has been established as an essential curative and palliative modality for early and advanced stages of the disease. Several studies have explored the role of very low-dose RT for palliation in indolent non-Hodgkin's lymphomas, demonstrating that this approach can lead to high rates of local control, and thereby, help improve the quality of life for these patients. While the most common schedule of very low-dose RT used in the palliative setting is 4Gy in 2 fractions, which was established in the landmark FoRT trial, this requires patients to be available for two RT sessions, increasing the financial and opportunity costs for the patient. Currently, data regarding the use of a single fraction of very low-dose RT (4Gy) for treating iNHLs in the palliative setting is still lacking. In this viewpoint, we aim to draw attention to this approach, where we emphasize the need for further exploration of the single-dose fractionation schedule as a non-toxic, simple, and easy treatment approach for iNHLs, which would inform future clinical trials to investigate this dose/fractionation.

查看原文本刊更多论文

由于惰性非霍奇金淋巴瘤（iNHLs）对放射线非常敏感，放射治疗（RT）已被确定为治疗早期和晚期淋巴瘤的一种重要的治愈和姑息方式。有几项研究探讨了极低剂量 RT 在姑息治疗惰性非霍奇金淋巴瘤中的作用，结果表明这种方法可实现较高的局部控制率，从而有助于改善这些患者的生活质量。虽然在姑息治疗中最常用的超低剂量 RT 计划是 4Gy 2 次分次注射，这是在具有里程碑意义的 FoRT 试验中确立的，但这需要患者接受两次 RT 治疗，从而增加了患者的经济成本和机会成本。目前，有关在姑息治疗中使用单次超低剂量 RT（4Gy）治疗 iNHL 的数据仍然缺乏。在这篇论文中，我们希望引起人们对这一方法的关注，并强调有必要进一步探索单剂量分次放射治疗计划，将其作为一种无毒、简单、方便的治疗 iNHLs 的方法，这将为未来研究这一剂量/分次放射治疗的临床试验提供依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.